UCR School of Medicine to Serve as Lead Site for Clinical Trial on Stuttering

UCR School of Medicine to serve as lead site for clinical trial on stuttering.   

The School of Medicine at the University of California, Riverside, will serve as lead site for a Phase 2 clinical trial evaluating ecopipam, an investigational first-in-class drug being tested for the treatment of stuttering in adults and Tourette syndrome in pediatric patients.  

Find the full article here: Emalex news release written by Evelyn M. O’Connor. 

This site uses cookies to improve your experience. Dismiss to continue or click to learn more about our privacy policy.

Learn More